Skip to main content
Medical information Clinical review pending

Genetic Testing

Pseudomonas Aeruginosa RNA Detection Qualitative Test

Detects the presence of Pseudomonas Aeruginosa bacteria, often associated with respiratory infections, especially in cystic fibrosis patients. This test uses RNA detection technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Sputum or throat swab (for cystic fibrosis patients), water sample. Confirm specific requirements with the laboratory before booking.
Results
Confirm turnaround time with the laboratory before booking.
Preparation
No specific patient preparation is required. Patients must sign a consent form and provide relevant clinical history.
Test priceKSh 11,560

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Pseudomonas Aeruginosa RNA Detection Qualitative Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected Pseudomonas Aeruginosa infection
  • ✓Patients with cystic fibrosis
  • ✓Individuals with chronic lung disease
  • ✓Immunocompromised patients
  • ✓Monitoring treatment effectiveness
  • ✓Investigation of respiratory symptoms
02

In plain language

What this test helps you understand

This test helps identify the presence of Pseudomonas Aeruginosa bacteria, aiding in the diagnosis and management of infections, particularly respiratory infections in vulnerable populations.
The Pseudomonas Aeruginosa RNA Detection Qualitative Test is a diagnostic tool used to identify the presence of Pseudomonas Aeruginosa bacteria. This bacterium is known to cause infections, particularly in individuals with weakened immune systems or underlying respiratory conditions like cystic fibrosis. The test uses Real Time RT-PCR technology to detect the bacteria's RNA, providing accurate results to guide medical decisions.

This test specifically looks for the genetic material (RNA) of Pseudomonas Aeruginosa in patient samples. It is valuable for diagnosing respiratory infections and can also be used to assess water samples in healthcare environments.

Early detection of Pseudomonas Aeruginosa is important for initiating appropriate treatment and preventing complications. This test can help monitor treatment effectiveness in patients with chronic conditions like cystic fibrosis.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Patients must sign a consent form and provide relevant clinical history.
SampleSputum or throat swab (for cystic fibrosis patients), water sample. Confirm specific requirements with the laboratory before booking.
MethodologyReal Time RT-PCR (Reverse Transcription Polymerase Chain Reaction)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the presence of Pseudomonas Aeruginosa RNA but does not provide information on antibiotic resistance. A negative result does not completely rule out infection if the bacterial load is very low or if the sample was collected improperly.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Pseudomonas Aeruginosa is a type of bacteria that can cause infections, particularly in people with weakened immune systems or lung conditions like cystic fibrosis.
Early detection of Pseudomonas Aeruginosa allows for timely treatment, which can help prevent severe infections and complications.
Samples typically include sputum or throat swabs from patients, or water samples. Please confirm the exact requirement with the lab.
The Real Time RT-PCR method used is highly accurate for detecting the presence of Pseudomonas Aeruginosa RNA.
A positive result indicates that Pseudomonas Aeruginosa RNA was detected in the sample. Your doctor will discuss the implications and next steps.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp